Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of KL-HIV-Tri01 in HIV Infected Subjects
NCT06117657Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, Trispecific Antibodies
01
Overview
Phase 1, open-label trial of KL-HIV-Tri01 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoints: Number and severity of AEs and SAEs at 52 weeks, Neutralizing Antibodies Against KL-HIV-Tri01 Capsid at 52 weeks and 2 more. Status: unknown.
02
Drugs
KL-HIV-Tri01
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06117657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06117657.